480 related articles for article (PubMed ID: 28137501)
1. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
2. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
[TBL] [Abstract][Full Text] [Related]
3. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
4. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
7. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
[TBL] [Abstract][Full Text] [Related]
9. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
10. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Bollmeier SG; Prosser TR
Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
[TBL] [Abstract][Full Text] [Related]
13. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
14. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
15. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
16. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
McKeage K
Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
[TBL] [Abstract][Full Text] [Related]
17. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D; Andersen L; Forth R; Jacques L; Yates L
J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
[TBL] [Abstract][Full Text] [Related]
18. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
[TBL] [Abstract][Full Text] [Related]
19. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
Rodrigo GJ; Neffen H
Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]